Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer

• Published in: Scientific reports Vol. 13; no. 1; p. 1258
• Main Authors: Stergiopoulou, Dimitra, Markou, Athina, Strati, Areti, Zavridou, Martha, Tzanikou, Eleni, Mastoraki, Sophia, Kallergi, Galatea, Georgoulias, Vassilis, Lianidou, Evi
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 23.01.2023; Nature Publishing Group UK; Nature Portfolio
• Subjects: Biomarkers, Tumor - genetics; Biopsy; Breast cancer; Breast Neoplasms - pathology; CD44 antigen; Disease management; DNA methylation; Early Detection of Cancer; Enumeration; Epithelial Cell Adhesion Molecule; ESR1 protein; Female; Gene expression; Humans; Immunofluorescence; Liquid Biopsy; Metastases; Minimal residual disease; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Cells, Circulating - pathology; Patients; Peripheral blood
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-25400-1

Liquid biopsy (LB) provides a unique minimally invasive tool to follow-up cancer patients over time, to detect minimal residual disease (MRD), to study metastasis-biology and mechanisms of therapy-resistance. Molecular characterization of CTCs offers additionally the potential to understand resistance to therapy and implement individualized targeted treatments which can be modified during the disease evolution and follow-up period of a patient. In this study, we present a long-term follow-up of operable breast cancer patients based on a comprehensive liquid biopsy analysis. We performed a comprehensive liquid biopsy analysis in peripheral blood of 13 patients with early-stage operable breast cancer at several time points for a period of ten years, consisting of: (a) CTC enumeration using the CellSearch system, (b) phenotypic analysis of CTCs using Immunofluorescence, (c) gene expression analysis, in EpCAM CTCs for CK-19, CD24,CD44, ALDH1, and TWIST1, (d) analysis of PIK3CA and ESR1 mutations in EpCAM CTCs and corresponding plasma ctDNA and (e) DNA methylation of ESR1 in CTCs. 10/13 (77%) patients were found negative for LB markers in PB during the whole follow-up period, and these patients did not relapse during the follow-up. However, 3/13(18%) patients that were positive for at least one LB marker relapsed within the follow-up period. The molecular characteristics of CTCs were highly different even for the same patient at different time points, and always increased before the clinical relapse. Our results indicate that liquid biopsy can reveal the presence of MRD at least 4 years before the appearance of clinically detectable metastatic disease demonstrating that a comprehensive liquid biopsy analysis provides highly important information for the therapeutic management of breast cancer patients.